Sanofi-Aventis Signs Collaborative Agreement With Johns Hopkins University
Posted on: Monday, 21 July 2008, 12:01 CDT
Sanofi-Aventis has signed a three year agreement with the division of allergy and clinical immunology of the Johns Hopkins University School of Medicine, Baltimore, Maryland.
Under the terms of this agreement, the partners will jointly work to discover and develop new ways of treating respiratory diseases, in particular severe asthma and chronic obstructive pulmonary disease (COPD), as well as immuno-allergic diseases.
For each research theme, Johns Hopkins ACI and Sanofi-Aventis will work on new target identification, assay development and compound screening. The two research organizations will also collaborate on the design of potential clinical studies and the selection of biomarkers.
Marc Cluzel, senior vice president of R&D at Sanofi-Aventis, said: "This collaboration will allow Sanofi-Aventis and Johns Hopkins allergy and clinical immunology to join their efforts to identify new therapeutic approaches, in particular in severe asthma and COPD. We are looking forward to working with Johns Hopkins on this endeavor."
Source: Datamonitor
Related Articles
- Sanofi Pasteur Announces Results of U.S. Clinical Trials of Influenza A (H1N1) Vaccine in Infants and Children
- Sanofi Pasteur Announces Results of U.S. Clinical Trials in Adults Following One Dose of Influenza A (H1N1) Vaccine
- ModSpace's MedBuild Team Provides 240,000 Louisiana Veterans With New Medical Care Facility
- Hanley Center Names D. John Dyben Clinical Director
- Johns Hopkins Selects Eceptionist Platform to Run Second Opinion Service
- Johns Hopkins to Run Middle Eastern Hospital
- Sanofi-Aventis and Regeneron Pharmaceuticals Expand Their VEGF Trap Oncology Collaboration to Japan
- Sanofi-Aventis Announces Strong Net Sales Growth in the First Half of 2005: 11.0% on a Comparable Basis(1)(2); Further Increase in Market Share(3) in the Second Quarter
- Spears, Costner and Berry Getting Stars
 |
 |
User Comments (0)
RSS Feeds